Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Nicole M Ondrush und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Mount Sinai Hospital, New York, New York, USA. Hauptthemen laut MEDLINE: Caliciviridae Infections, Organ Transplantation, Norovirus, Immunoglobulins. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Norovirus gastroenteritis can cause serious complications in solid organ transplant (SOT) recipients, and no licensed treatment is available. Typical therapy is supportive care; however, some medications may be used off‐label. Serum‐derived bovine immunoglobulin (IG), a medical food product, has been utilized off‐label for norovirus gastroenteritis, although clinical efficacy is uncertain. The objective of this study was to evaluate the outcomes of SOT recipients who received serum‐derived bovine IG for the treatment of norovirus.
Methods
Adult SOT recipients, who received serum‐derived bovine IG as treatment for norovirus between January 2020 and December 2024, were evaluated for inclusion. Outcomes evaluated included improvement in the number of bowel movements to less than three per day, presence of more formed bowel movements, presence of acute kidney injury (AKI), initial response rates, and 90‐day relapse‐free rate.
Results
14 SOT recipients were included. Nine patients had a history of prior norovirus gastroenteritis. Reduction to less than three bowel movements per day occurred in 8/14 (57%) patients. Overall, 12/14 (86%) patients experienced clinical improvement after a median of 4.5 days of serum‐derived bovine IG. Of those alive at 90‐day follow‐up, 8 of 10 (80%) did not experience relapsing norovirus infection.
Conclusion
Orally administered serum‐derived bovine IG may be a potential option for SOT recipients with chronic norovirus infection. Larger, well‐designed studies are needed to further define its clinical efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.
- Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Nicole M Ondrush, Meenakshi Rana, Timothy Sullivan
Zitieren
APA
Ondrush, N. M., Rana, M., Patel, G., Chasan, R., & Sullivan, T. (2026). Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection. Clinical Transplantation. https://doi.org/10.1111/ctr.70630
Vancouver
Ondrush NM, Rana M, Patel G, Chasan R, Sullivan T. Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection. Clinical Transplantation. 2026. doi:10.1111/ctr.70630
BibTeX
@article{Ondrush2026,
author = {Ondrush, Nicole M and Rana, Meenakshi and Patel, Gopi and Chasan, Rachel and Sullivan, Timothy},
title = {Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70630}
}
EUVIMED